MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 3, 2006--BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty biopharmaceutical company focused on acute care products, including pain therapies has purchased from QLT USA, Inc. (“QLT USA”), a subsidiary of QLT Inc. (NASDAQ:QLTI; TSX:QLT) all of the non-U.S. rights to the BEMA(TM) drug delivery technology, including all patent rights and related intellectual property. Prior to this transaction, BDSI had licensed BEMA(TM) from QLT USA on a worldwide, exclusive basis. Besides the rights to the BEMA(TM) technology outside of the U.S., the agreement gives BDSI an option to purchase the U.S. BEMA(TM) technology patents within 12 months.
